The efficacy of NexGard® and NexGard Spectra® against sarcoptic mange in dogs was evaluated in a clinical field study. Skin scrapings from dogs presenting signs suggestive of sarcoptic mange were examined to confirm infestation. A total of 106 dogs were screened at eight sites in Portugal and Germany. In all, 80 dogs that had demonstrated ≥5 live Sarcoptes mites in five skin scrapings were enrolled, scored for specific clinical signs (pruritus; papules and crusts; alopecia), and allocated at random to receive either NexGard® or NexGard Spectra® twice, one month apart per label instructions. To determine efficacy, live Sarcoptes mites in five skin scrapings per dog were counted, and clinical signs were scored one month and two months after first treatment and compared to pre-treatment (baseline) values. Based on compliance, 65 dogs were determined to be evaluable cases at the end of the study. The efficacy, in terms of reduction of geometric mean live Sarcoptes mite counts, was 98.9% and 99.7% for NexGard®-treated (n = 38) and 99.6% and 100% for NexGard Spectra®-treated dogs (n = 27) at one month and two months after treatment initiation (p < 0.001, both treatments). Both treatments resulted in a significant improvement in pruritus, papules and crusts, and alopecia one month and two months after treatment initiation (p = 0.0001, both treatments). In conclusion, this field study confirms that both NexGard® and NexGard Spectra® administered twice one month apart provide an effective and safe treatment against sarcoptic mange in dogs.

Background: Recombinant feline interferon-v (rFeIFN-v) was tested as a treatment option for cats with fibrosarcoma to assess safety and feasibility.Hypothesis: Treatment with rFeIFN-v in cats with fibrosarcoma is safe and feasible. Animals: Twenty domestic cats. Methods:In an open-labeled uncontrolled clinical trial 12 injections of 1 3 10 6 U/kg rFeIFN-v were administered over a 5-week period: the 1st through 4th injections were given intratumorally, and the 5th through 12th injections were administered subcutaneously at the tumor excision site. Wide surgical excision of the tumors was carried out after the 4th injection and before the 5th injection of rFeIFN-v. A Common Terminology Criteria for Adverse Events (CTCAE) analysis was conducted. Flow cytometry of fibrosarcoma cells after incubation with rFeIFN-v and recombinant feline interferon-c was performed to assess the biological effect of rFeIFN-v.Results: Changes in blood cell count, increases in serum aspartate-amino-transferase activity, serum bilirubin concentration, serum creatinine and serum electrolyte concentrations, weight loss, anorexia, increased body temperature, and reduced general condition were observed but were mostly minor (grade 1 and 2) and self limiting. Eosinophilia (P 5 .025), neutropenia (P 5 .021), and weight loss (P , .001) were statistically correlated with rFeIFN-v-treatment (analysis of parameters before treatment and after 3 injections of rFeIFN-v). Flow cytometry of 5 unrelated feline fibrosarcoma cell lines showed increased expression of major histocompatibility complex (MHC) class I molecules (P 5 .026) in response to in vitro incubation with rFeIFN-v, whereas expression of MHC class II molecules was not affected significantly.Conclusions and Clinical Importance: RFeIFN-v for the treatment of feline fibrosarcoma is safe, well tolerated, and can be easily performed in practice. To assess the efficacy of the treatment, it should be tested in a placebo-controlled trial.

Background: Recombinant feline interferon-v (rFeIFN-v) was tested as a treatment option for cats with fibrosarcoma to assess safety and feasibility.Hypothesis: Treatment with rFeIFN-v in cats with fibrosarcoma is safe and feasible. Animals: Twenty domestic cats. Methods:In an open-labeled uncontrolled clinical trial 12 injections of 1 3 10 6 U/kg rFeIFN-v were administered over a 5-week period: the 1st through 4th injections were given intratumorally, and the 5th through 12th injections were administered subcutaneously at the tumor excision site. Wide surgical excision of the tumors was carried out after the 4th injection and before the 5th injection of rFeIFN-v. A Common Terminology Criteria for Adverse Events (CTCAE) analysis was conducted. Flow cytometry of fibrosarcoma cells after incubation with rFeIFN-v and recombinant feline interferon-c was performed to assess the biological effect of rFeIFN-v.Results: Changes in blood cell count, increases in serum aspartate-amino-transferase activity, serum bilirubin concentration, serum creatinine and serum electrolyte concentrations, weight loss, anorexia, increased body temperature, and reduced general condition were observed but were mostly minor (grade 1 and 2) and self limiting. Eosinophilia (P 5 .025), neutropenia (P 5 .021), and weight loss (P , .001) were statistically correlated with rFeIFN-v-treatment (analysis of parameters before treatment and after 3 injections of rFeIFN-v). Flow cytometry of 5 unrelated feline fibrosarcoma cell lines showed increased expression of major histocompatibility complex (MHC) class I molecules (P 5 .026) in response to in vitro incubation with rFeIFN-v, whereas expression of MHC class II molecules was not affected significantly.Conclusions and Clinical Importance: RFeIFN-v for the treatment of feline fibrosarcoma is safe, well tolerated, and can be easily performed in practice. To assess the efficacy of the treatment, it should be tested in a placebo-controlled trial.